Effect of noodles containing calcium alginate on postprandial blood sugar levels -Placebo-controlled, randomized, double-blind, crossover study-

Effect of noodles containing calcium alginate on postprandial blood sugar levels -Placebo-controlled, randomized, double-blind, crossover study- - Effect of noodles containing calcium alginate on postprandial blood sugar levels

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000053439

Enrollment

Registered

2024-01-30

Start date

2024-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

Stage I: Placebo noodles Stage II: Alginic acid-containing noodles A Stage III: Alginic acid-containing noodles B Eat the test food in 5 minutes. *The order of intervention will be Stage I, St

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Men and women who are 18 years of age or older at the time of obtaining consent. Persons who have fully understood and consented to the purpose and safety of this research specified in the Research Cooperation Consent Manual.

Exclusion criteria

Exclusion criteria: Persons who are taking medicines or supplements that may affect sugar metabolism. Currently undergoing treatment for diabetes or who is judged to need treatment. Persons with serious diseases such as diabetes, liver disease, kidney disease, hypertension, ischemic heart disease, digestive system disease, etc., or those with a history of such diseases. Persons who have some kind of disease and are receiving medication and are deemed unsuitable as subjects by the research doctor. person. Persons who regularly use medicines, health foods, or supplements that affect blood lipids. Persons who are at risk of developing allergic symptoms regarding the test noodles (flour, etc.). Persons whose BMI value obtained from the temporary registration questionnaire falls outside the 95% confidence interval from the average BMI value of all applicants. Persons whose fasting blood sugar level is higher than 125 mg/dL or lower than 60 mg/dL as a result of the screening test. Persons whose HbA1c (NGSP) value is 6.5% or higher as a result of the screening test. If any of the screening test results are positive for HIV antigen/antibody, HBV, HCV, or syphilis. Persons with obvious abnormalities found in hematological or biochemical tests.

Design outcomes

Primary

Measure	Time frame
Maximum postprandial blood sugar level (Cmax)	—

Secondary

Measure	Time frame
Area under the postprandial blood glucose level time curve AUC (0-120 minutes) Blood sugar levels at each measurement point (before meals, 15, 30, 45, 60, 90, 120 minutes after meals)	—

Countries

Japan

Contacts

Public ContactSatsuki Kimura

Takasaki University of Health and Welfare Faculty of Pharmacy

s-kimura@takasaki-u.ac.j0273521180

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026